BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 136 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,844,000 | -64.3% | 305,095 | -54.0% | 0.51% | -57.5% |
| Q1 2022 | $10,775,000 | +241.7% | 662,644 | +202.0% | 1.21% | +160.2% |
| Q3 2021 | $3,153,000 | -41.7% | 219,450 | -35.9% | 0.46% | -30.6% |
| Q2 2021 | $5,410,000 | +12.6% | 342,185 | -27.6% | 0.67% | +8.6% |
| Q1 2021 | $4,806,000 | +166.4% | 472,520 | +113.3% | 0.62% | -3.4% |
| Q1 2019 | $1,804,000 | – | 221,565 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |